Takeda Bolsters IBD Pipeline by Partnering with Prometheus Biosciences
By Subham Nandi
Pharma Deals Review: Vol 2019 Issue 10 (Table of Contents)
Published: 26 Oct-2019
DOI: 10.3833/pdr.v2019.i10.2465 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Takeda has partnered with US-based Prometheus Biosciences to develop and commercialise therapies for inflammatory bowel disease (IBD) in a deal worth more than US$420 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS